Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

JAMA Ophthalmology - United States
doi 10.1001/jamaophthalmol.2016.0379
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

American Medical Association (AMA)

Related search

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Clinical Risk Factors for Poor Anatomic Response to Ranibizumab in Neovascular Age-Related Macular Degeneration§

Open Ophthalmology Journal
Ophthalmology
2014English

Effect of ARMS2 Gene Polymorphism on Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2016English

Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration

European Ophthalmic Review
2012English

Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2013English

Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment

Journal of Clinical & Experimental Ophthalmology
2012English

Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up

Clinical Ophthalmology
Ophthalmology
2016English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy